|
John Fielding,
CEO
|
Pharmaceutical companies maintain that dramatic profit margins are necessary to cover the cost of research and development for both drugs that make it to market and those that fail.
Pharmaceutical Profiles is an early phase development company focused on improving the decision making process in drug/product development.
Acusphere is a privately held specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology.
|
|
Brian Mengel,
Civil Servant
|
After drugs are selected on their clinical merits and on the basis of their financial impact on those without drug coverage, contractual arrangements with pharmaceutical manufacturers may be evaluated.
The Drugs and Pharmaceutical Research Program is one such activity and was initiated in 1995 to enhance the capabilities of the Indian Drugs and Pharmaceutical industries towards development of new drugs.
The pharmaceutical companies are actively seeking improved oral drug delivery systems which address the limitations and the problems associated with existing technology.
|
|
Mike Enlow,
Internet Marketer
|
The pharmaceutical industry is making millions of dollars selling drugs and they spend a lot of money advertising those drugs.
|
|
Dave Simons,
Internet Entrepeneur
|
OSI Pharmaceuticals is a leading drug discovery company with a substantial pipeline of product opportunities for commercialization with the pharmaceutical industry.
Q3DM is developing a drug discovery platform focused on providing pharmaceutical companies with solutions geared toward replenishing the drug discovery pipeline with new drugs and novel targets at a rapid rate.
|
|
Arthur Dawkins,
Astro-physicist
|
Pharmaceutical companies involved in development of new drugs must conduct extensive preclinical research before beginning research of the new compound on human subjects.
Pharmaceutical companies are changing the way they manufacture drugs based on their understanding of the function of genes and the proteins they make.
He is associated with several pharmaceutical companies as a clinical researcher into new drug therapies and often seeks patients to participate in the final phases of FDA trials.
|
|
|
